Genentech Builds Tarceva Inventory Following Iressa's Failed Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech has been building inventory for its non-small cell lung cancer agent Tarceva (erlotinib) following AstraZeneca's announcement that Iressa (gefitinib) failed to show a statistically significant survival benefit
You may also be interested in...
Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005
Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.
Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005
Firms release positive survival data from pivotal trial of Tarceva in combination with Lilly’s Gemzar. Investigators believe pancreatic cancer is a “logical place to look” for expanded use of EGFR inhibitors like Tarceva.
Genentech's Avastin Gaining Market Share In On- And Off-Label Indications
Avastin's share in the first-line metastatic colorectal cancer setting reached 55% in the fourth quarter, up from 42% in the third quarter. Off-label use in the second-line increased to 41%. An August "Dear Doctor" letter on thromboembolic events may have had an impact on slower-than-expected fourth quarter sales of the oncologic.